AcariaHealth announced that it has been selected by Sarepta Therapeutics, as part of the limited distribution network for ELEVIDYS, delandistrogene moxeparvovec-rokl,. ELEVIDYS, an adeno-associated virus-based gene therapy, is approved for the treatment of ambulatory pediatric patients aged four through five years with Duchenne muscular dystrophy, DMD, with a confirmed mutation in the DMD gene. This indication was approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin observed in patients treated with ELEVIDYS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SRPT:
- Sarepta announces sale of priority review voucher for $102M
- Biotech Alert: Searches spiking for these stocks today
- Evercore downgrades Sarepta, says path to expand Elevidys label unclear
- Morgan Stanley says Elevidys label unlikely to have near-term impact on Catalent
- Sarepta price target lowered to $161 from $204 at Citi